Chain Bridge I 8-K filings

Chain Bridge I has amended its Senior Note with C/M Capital Master Fund LP, extending the maturity date and modifying default conditions, while also issuing new notes for general corporate purposes.

Chain Bridge I shareholders approved an extension of the deadline to complete an initial business combination to November 15, 2026, alongside significant share redemptions.

Chain Bridge I has issued an unsecured, non-interest bearing promissory note for $1.25 million to C/M Capital Master Fund LP to fund its initial business combination and general corporate purposes.

Chain Bridge I has entered into an agreement with Fulton AC I LLC to extend its business combination deadline to November 15, 2026, supported by new capital contributions to the trust account.

Chain Bridge I and CommLoan have signed a non-binding Letter of Intent for a business combination, aiming to create a new public company focused on commercial real estate fintech.

Chain Bridge I files an amendment to its previous 8-K report to include the auditor letter from Frank, Rimerman + Co. LLP, following the termination of their engagement and the engagement of RBSM, LLP.

Chain Bridge I terminated its business combination agreement with Phytanix Bio and changed its independent accounting firm following the discovery of a material weakness in internal controls and the need to restate financial statements.

Chain Bridge I's Audit Committee determined that previously issued financial statements for the three and nine month periods ended September 30, 2024, should no longer be relied upon due to an error understating a promissory note liability.

Chain Bridge I will be delisted from Nasdaq on November 19, 2024, but has secured a one-year extension to complete its business combination, with shares moving to the OTC market.

Chain Bridge I is set to be delisted from the Nasdaq after failing to complete a business combination within the required timeframe, with trading of its securities to be suspended on November 19, 2024.

Chain Bridge I has entered into agreements with investors to reverse share redemptions and secure additional funding, aiming to extend its deadline for completing a business combination.

Chain Bridge I has postponed its Extraordinary General Meeting to November 14, 2024, and extended the deadline for shareholders to redeem their Class A ordinary shares to November 12, 2024.

Chain Bridge I has entered into an agreement with Fulton AC I LLC, where Fulton will reimburse up to $100,000 to cover dissolution expenses if the company is dissolved.

Chain Bridge I has been notified by Nasdaq that it has regained compliance with the minimum public holder requirement.

Chain Bridge I has announced a business combination agreement with Phytanix Bio, a company focused on developing cannabinoid-based pharmaceuticals.

Phytanix Bio, a preclinical stage pharmaceutical company specializing in cannabinoid and cannabinoid-like medicines, is set to merge with Chain Bridge I, a special purpose acquisition company, to become a publicly listed entity.

Chain Bridge I has entered into a $1.59 million loan agreement with Phytanix Bio to cover working capital, transaction expenses, and general corporate needs.

Chain Bridge I received a notice from Nasdaq for not meeting the minimum public holder requirement and has 45 days to submit a plan to regain compliance.

Chain Bridge I has announced the resignation of its CFO, Roger Lazarus, and the appointment of Andrew Kucharchuk as his successor, effective April 1, 2024.

Chain Bridge I has appointed Oliver Wiener as a new independent director, increasing the board size to five, and named him to the audit committee, while also granting him 50,000 restricted stock units upon a business combination.

Chain Bridge I shareholders approved an extension to the deadline for completing a business combination, while a significant number of shares were redeemed.

Chain Bridge I has amended its previous 8-K filing to include additional details regarding the independence of its new directors and their compensation.

Chain Bridge I's board of directors has approved a one-month extension to its business operations deadline, now set for February 15, 2024.